Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland

Introduction

Subsequent to the first wave of the coronavirus disease 2019 (COVID-19) pandemic (1), clusters of children presenting with unusual multisystem inflammatory conditions emerged (2, 3). The clinical syndrome showed some heterogeneity with patients presenting either akin to toxic shock, Kawasaki-disease like or with undifferentiated inflammatory characteristics, in addition to evidence of current or past COVID-19 infection in the majority of cases (4, 5). Accordingly, this new disease entity has been called Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS) as per the Royal College of Pediatrics and Child Health case definition (RCPCH) (6) and Multisystem Inflammatory Syndrome associated with COVID-19 (MIS-C) as per the Center for Disease Control (CDC) (7) and the WHO (World Health Organisation) (8).

While a number of studies have attempted to explain the underlying biological and genetic mechanisms of PIMS-TS, its pathophysiology and the observed variation in clinical presentation remains largely unknown (9–11). It is currently assumed that a complex process involving SARS-CoV-2-specific antigen presentation to autoreactive T cells, superantigen-like viral structures, cross-reactive SARS-CoV-2-specific antibodies and unbalanced cytokine responses may initiate PIMS-TS in genetically predisposed children (12–16). In other pediatric hyperinflammatory syndromes, such as Kawasaki disease (KD), macrophage activation syndrome (MAS), and hemophagocytic lymphohistiocytosis (HLH), timely initiation of anti-inflammatory therapy and immunosuppression can often reverse the hyper-inflammatory state and prevent or mitigate organ damage. Therefore, therapeutic immune modulation is widely used as a mainstay of PIMS-TS treatment with the aim to inhibit cytokine secretion and restore immune homeostasis. In addition, PIMS-TS patients may also show signs of vasculitis, endothelial damage, and thrombosis, hence antiplatelet and anticoagulation management in PIMS-TS represent important additional considerations (17).

Cardiac involvement includes a supposed post-infectious myocarditis or myocardial injury and the development of coronary artery abnormalities with a minority developing coronary artery abnormalities. Myocardial injury is thought to be attributed to an acute and dysregulated immune response related to cytokine storm, endothelial damage, microvascular dysfunction, and ischemic injury (18). The tropism of SARS-Cov-2 to myocytes and endothelial cells with the facilitated entry by binding to the angiotensin-converting enzyme 2 receptors may contribute to the high percentage of cardiac involvement (19).

In order to standardize management in Switzerland, we aimed to develop best practice recommendations for the diagnosis and treatment of children with PIMS-TS.

Statement of Uncertainty

At present, professionals remain confronted with substantial uncertainties regarding clinical phenotypes, long-term outcomes, and optimal management (20). In the absence of randomized trials, evidence for best treatment is minimal for the diagnostic, anti-inflammatory, anti-infectious, and supportive measures which have been proposed (9, 21). Recommendations therefore are based primarily on expert opinion and similar recommendations in the United Kingdom. The field is rapidly changing with reports being published on an almost weekly basis (22, 23), hence revision and updates of the recommendations will be required regularly.

Methods

Subsequent to a call for Expressions of Interest, the Interest Group for Pediatric and Neonatal Intensive Care (IGPNI) of the Swiss Society of Intensive Care Medicine (SSICM) and the Pediatric Infectious Diseases Group Switzerland (PIGS) formed a working group on PIMS-TS. In total, 24 panelists across the fields of pediatric intensive care, infectious diseases, immunology and rheumatology, hematology, cardiology, and nursing composed the panel.

Four subgroups focused on the domains of (i) disease criteria and diagnosis, (ii) anti-inflammatory therapies, (iii) anti-infective therapies, and (iv) additional support therapies including coagulation management. Each subgroup performed a focused literature review on publications since the description of PIMS-TS in early 2020 until December 2020. In addition, we searched for available pathways, diagnostic, therapeutic, and follow-up recommendations from different international institutions (24–27). Over a period of 5 weeks, weekly virtual meetings of the entire working group were held to develop and discuss the recommendations in a modified Delphi process. Finally, voting was performed by the entire panel for each recommendation using Survey Monkey. The threshold for recommendations was met if >80% of panelists voted for full agreement on an item. The thereby developed guideline was piloted during 4 weeks in January 2021, subsequent to which an update and re-voting occurred on items which were agreed to be changed in the panel.

Recommendations

Diagnosis

1. For PIMS-TS, the following case definition should be used:

Adapted RCPCH—case definition (6, 28)

• Patient aged <18 years of age. Persistent fever + inflammation (elevated CRP and neutrophils, or lymphopaenia) + single or multiorgan dysfunction (shock, cardiac, respiratory, renal, gastrointestinal, neurological) + additional features (see Table 1). This may include children fulfilling full or partial criteria for Kawasaki disease (KD).

• Exclusion of any other probable cause, such as bacterial sepsis, staphylococcal/streptococcal shock syndromes, and viral infections associated with myocarditis. Waiting for these results should not delay seeking expert advice.

• Positive for current or recent SARS-CoV-2 infection by PCR, serology, or antigen test; or COVID-19 exposure within 4 weeks prior to the onset of symptoms. Waiting for these results should not delay seeking expert advice.

2. If a child fulfills the diagnostic criteria for PIMS-TS we recommend classifying these patients according to the presenting phenotype due to the implications for diagnostic workup and management:

• Shock-like presentation: signs of shock as per the Goldstein 2005 definition of cardiovascular failure (29) (Appendix)

• Kawasaki disease-like presentation: complete or incomplete with cardiac involvement, according to AHA (30)

• Undefined inflammatory presentation: persistent pyrexia with signs of PIMS-TS but not meeting shock criteria nor having cardiac involvement.

TABLE 1

Table 1. List of diagnostic criteria for PIMS-TS.

Overall, PIMS-TS remains a rare condition and most children with SARS-CoV-2 infection will remain asymptomatic or will exhibit only mild symptoms (4, 31). Predominant clinical features include persistent fever and gastrointestinal symptoms, e.g., abdominal pain, vomiting or diarrhea. Many patients may exhibit additional clinical features (Table 1). Cardiovascular impairment can be manifest at presentation or develop during admission (18, 32). Coronary artery aneurysms (CAA) may develop post-discharge up to 3 weeks after disease onset (30). Some patients show rapid clinical deterioration often characterized by a vasoplegic shock state requiring admission to intermediate or intensive care units (IMC/PICU) (4, 33).

It is paramount to avoid anchoring bias given that PIMS-TS remains a rare condition (34), and in view of the fact that many children suffering from other disease during the pandemic may have concomitant microbiological evidence of SARS-CoV-2 exposure. Other, more common differential diagnoses need to be considered, such as but not restricted to:

– Invasive bacterial infection

– Sepsis

– Toxic shock syndrome (TSS)

– Staphylococcal Scalded Skin Syndrome (SSSS)

– Kawasaki disease (KD)

– Viral myocarditis/infection (such as EBV, CMV, adenovirus, enterovirus, and other viruses)

– Serum sickness

– Acute appendicitis/acute surgical abdomen

– Gastroenteritis

– Macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH) (Appendix)

– Malignant diseases, e.g., acute leukemia.

As pediatric Emergency Departments face large numbers of febrile children, we recommend a staged diagnostic approach, starting with standard investigations for all children where PIMS-TS is suspected (Table 2), followed by more in-depth diagnostic work-up in children with evidence of severe disease, or those with diagnostic uncertainty.

TABLE 2

Table 2. Recommendations for diagnostic work-up in children evaluated for PIMS-TS.

PIMS-TS may manifest with features of classic or incomplete (atypical) KD with, or without cardiac involvement (30). Although the clinical presentation of PIMS-TS patients shares similarities with KD and TSS (4, 31), there are several differences in the clinical presentation compared to classical KD and patients with PIMS-TS by definition lack microbial confirmation of a staphylococcal or streptococcal infection. Compared to classical KD, patients with PIMS-TS more often present with prominent gastrointestinal and neurologic symptoms (18), and the incidence of cardiac involvement is even higher in PIMS-TS patients. More than 50% of children with PIMS-TS do develop some sort of cardiac involvement, defined by elevation of cardiac biomarkers, systolic or diastolic myocardial dysfunction or even shock. In addition, there is limited evidence that conduction abnormalities are more common in PIMS-TS, including heart block (35, 36).

Early involvement of a pediatric multidisciplinary team (MDT) including intensive care, immunology, infectious diseases, rheumatology, cardiology, hematology, and others (e.g., general surgery) should be considered. In addition to cardiac biomarkers (such as cTnT and NT-pro-BNP) the cardiac evaluation of a patient with PIMS-TS should include a 12-lead electrocardiogram and echocardiography (Table 2). Diagnostic measures, including laboratory tests such as markers of inflammation and organ dysfunction, and imaging modalities such as transthoracic Doppler 2D echocardiography should be repeated sequentially depending on the presentation, disease severity, and evolution to guide escalation and de-escalation of therapy, and to rule out other diagnoses.

A substantial proportion of children with PIMS-TS initially manifest significantly raised levels of NT-pro-BNP and modest elevations of cardiac troponin, which sometimes take days to weeks to normalize (19, 32). In patients with preserved ejection fraction, increased cardiac biomarkers likely reflect subclinical myocardial injury and may be associated with more subtle changes in diastolic function (37). Commonly observed echocardiographic findings include depressed systolic LV and RV function. Moreover, mitral regurgitation, and mild pericardial effusion have been described. While most patients show rapid improvement in LV systolic function and even normalization within 1–2 weeks after initial presentation, diastolic dysfunction often persists until early follow up or longer (37).

ECG registration is recommended at the time of diagnosis and every 48 h while inpatient, daily in patients on PICU. Most ECG findings are non-specific and include ST-segment changes, QTc prolongation and premature atrial or ventricular beats. Another common finding is first-degree (rarely higher grade) atrioventricular block—which may progress after initial diagnosis (35, 36). Single cases of atrial fibrillation or sustained arrhythmias leading to hemodynamic collapse have been described (38). All inpatients should be monitored by telemetry. In well patients with unremarkable ECG recording, oxygen saturation and heart rate monitoring is deemed to be sufficient. In outpatients with first-degree atrioventricular block or arrhythmias Holter monitoring is recommended (27).

Coronary artery aneurysms represent a serious complication and may place patients at risk for coronary artery thrombosis or stenosis, myocardial infarction and cardiac death. Coronary artery abnormalities have been reported to appear in 8–24% of patients with PIMS-TS irrespective of the phenotype (18, 32). Most of them are dilation or small aneurysms, but large/giant aneurysms may occur (38), even during the convalescent period (4, 39). While, coronary artery dilation resolve within 4–8 weeks without sequelae, aneurysms may lead to coronary artery stenosis and thrombosis even when they reduce in size over weeks to months (30).

Anti-inflammatory Therapies

3. Therapeutic immune-modulation in PIMS-TS patients requires a multidisciplinary approach. Clinicians should re-evaluate the patient response and consider differential diagnoses at every step.

We recommend a MDT approach to guide initiation, escalation, and tapering of empiric immunomodulatory therapy, particularly because available evidence for such treatment is currently only based on observational reports. The panel recommends using a management algorithm (Figure 1) to guide the step-wise selection of the initial interventions. Dosing recommendations are provided in Table 3 and were adapted from the Imperial College Healthcare NHS Trust PIMS-TS guideline (Prof. Elizabeth Whittaker, personal communication).

4. In patients with Kawasaki disease-like PIMS-TS, immunomodulation and management should follow established guidelines for Kawasaki disease.

5. In patients with PIMS-TS shock, we recommend using immunoglobulins (IVIG, 2 g/kg).

6. In patients with PIMS-TS shock we recommend treatment with intravenous pulse high-dose methylprednisolone (10 mg/kg q24 h for 1–3 days, max. 1 g/day).

7. In non-shocked patients with PIMS-TS undefined inflammatory presentation clinicians should consider administration of immunoglobulins (IVIG, 2 g/kg).

8. In non-shocked patients with PIMS-TS (Kawasaki-like presentation or undefined inflammatory presentation) clinicians should consider administration of prednisolone (2 mg/kg q24 h, max. 60 mg/day).

9. In all patients with confirmed PIMS-TS treated with steroids, steroids should be tapered over a period of 2–6 weeks depending on the clinical course and considering the clinical and biochemical (such as CRP, D-Dimer, and ferritin levels) response.

FIGURE 1

Figure 1. PIMS-TS diagnostic and therapeutic algorithm.

TABLE 3

Table 3. Anti-inflammatory therapies in patients with PIMS-TS.

For children with Kawasaki disease-like PIMS-TS and for children with coronary artery abnormalities irrespective of the PIMS-TS phenotype, the panel recommends that established institutional or international guidelines such as the 2020 American College of Rheumatology guidelines (40) on Kawasaki disease-like PIMS-TS should be followed. In addition, both the European SHARE initiative (41) and the American Heart Association guidelines (30) provide guidance on KD.

We recommend, based on currently available reports and in line with other recommendations, to use intravenous immunoglobulin (IVIG) in PIMS-TS patients presenting with shock, and to consider IVIG in PIMS-TS with undefined presentation. While IVIG should be usually administered as a single dose of 2 g/kg (max. 100 g/dose), clinicians should assess the cardiac and fluid status, particularly in patients in shock, as in some patients a slower administration become necessary.

While corticosteroids have often been used as adjuncts to IVIG (42), the specific indication, dosing, timing or type of glucocorticoids in PIMS-TS remains unknown. A French propensity-matched study of 111 children with PIMS-TS reported substantially improved outcomes in children with PIMS-TS treated with IVIG and steroids (9% persistence of fever) in comparison to children who received IVIG alone (51% treatment failure, Odd's ratio 0.25; 95%-CI 0.09–0.70, p-value 0.008) (43). The panel considered that benefit vs. harm justify pulse high-dose steroids for a duration of 1–3 days in PIMS-TS patients with shock, with an initial dose of 10 mg/kg methylprednisolone (max 1 g/day). Increasing the methylprednisolone dose to 30 mg/kg q24 h may be considered, although side effects such as hyperglycemia, hypertension, agitation, hospital-acquired infection, and hip osteonecrosis should be weighed against potential benefit. PIMS-TS patients treated with pulse corticosteroids should receive gastric protection with proton-pump inhibitors.

Given potential side effects and the lack of data, we advise against the use of pulse steroids in PIMS-TS patients without shock but suggest considering a lower dose therapy given intravenously (up to 2 mg/kg/day) and, subsequently, orally. While the optimal duration of steroid therapy in PIMS-TS remains unknown, the joint view of the panel is that decisions on steroid treatment duration should be guided by the clinical response (resolution of signs and symptoms), as well as by laboratory evidence of decreasing inflammation and improving organ function. Most patients seem to recover well under a 14-day treatment schedule without subsequent signs of disease rebound. In patients with apparent rebound, alternative inflammatory diagnoses should be considered.

A proportion of patients may not respond to initial treatment, and deterioration of the disease can be life-threatening. Refractory PIMS-TS is characterized by persistent fever and/or increase of inflammatory markers, worsening organ function, or increase in need of vasoactive drugs [measured by Vasoactive-Inotrope Score (44)] within 24–48 h after start of treatment. Consideration of disease severity in particular in PICU patients, and assessing evidence of persistent or progressive (multi-) organ dysfunction is paramount to guide treatment escalation.

Again, MDT assessment is recommended and needs to take differential diagnoses into account at every step before escalating treatment, and should carefully evaluate risk-vs.-benefit ratio of escalating immunomodulatory therapies. For example, PIMS-TS patients may develop secondary infections and immuno-suppressive treatment regimens may further impair the host defense against infection. The current list of biological drugs includes IL-1R (i.e., anakinra), IL-6R (i.e., tocilizumab) and tumor necrosis factor (TNF) (infliximab) blocking agents (Table 3). In addition, clinicians may discuss administration of a second dose of IVIG, or pulse steroids.

10. In patients with PIMS-TS refractory to initial treatment with IVIG and steroids, and after exclusion of alternative causes by the multidisciplinary team, we suggest consideration for anakinra. We recommend starting at 2–3 mg/kg q12 h s.c. (max. 100 mg/dose, total of 4–6 mg/kg/day). In case of clinical improvement, stopping of anakinra after 48–72 h should be considered in the multidisciplinary team.

11. In patients with PIMS-TS where no clinical and biochemical improvement to anakinra treatment is observed within 24–48 h, the multidisciplinary team should consider other targeted immunomodulation therapy with either tocilizumab or infliximab.

12. Clinical assessment and serial laboratory testing on measures of inflammation and organ dysfunction should guide escalation and duration of immunomodulation therapy treatment.

Despite its limited licensed indication, anakinra is increasingly chosen for off-label use in PIMS-TS patients (4, 45–47). Anakinra has been approved for subcutaneous administration, however continuous intravenous administration has been reported (48). Its short half-life (4–6 h) (Table 3), allows for repeated re-assessment of the immunosuppressive regimen. We therefore suggest a short trial of IL-1R blockade in PICU-hospitalized PIMS-TS patients that have not responded within a period of 24–36 h following administration of both IVIG and steroids. Anakinra dose increase in the absence of clinical improvement may be considered in the MDT. We suggest stopping anakinra after 48–72 h without tapering in case of clinical improvement. There is no evidence to support routine serial cytokine level assessment to guide cytokine-targeted therapy (CTT) (49).

Tocilizumab is an IL-6R blocking agent currently approved for the treatment of both systemic and polyarticular juvenile idiopathic arthritis in children above 2 years of age. Tocilizumab has also been used in children with PIMS-TS as IL-6 has been described to be one of the main drivers of the inflammatory cytokine storm in this disease entity. However, safety concerns exist as significant side effects have been described such as a reversible elevation of liver enzymes and an increased risk for bacterial and fungal infections (Table 3). Therefore, tocilizumab should be reserved for children with life-threatening PIMS-TS in whom anakinra has failed to show a clear benefit within 48 h. Given the long half-life (150 h) tocilizumab is usually given as a single intravenous dose.

The TNF-alpha blocking agent infliximab, classically used in children with various autoimmune inflammatory diseases has also been successfully used in children with KD. However, since infliximab increases the risk for secondary infections, and based on its long half-life (around 8 days, Table 3), infliximab should be administered as a single intravenous dose, and only in patients with PIMS-TS who failed to respond to anakinra (or tocilizumab).

Anti-infective Therapies

13. Based on the absence of evidence of remdesivir treatment for children with COVID-19 and the proposed post-infectious concept of PIMS-TS (50) we do not recommend the routine administration of remdesivir in PIMS-TS patients.

14. Children with suspected PIMS-TS and signs of shock or other organ dysfunction should be treated empirically with intravenous broad-spectrum antimicrobial therapy for bacterial sepsis.

15. In children with PIMS-TS receiving intravenous antimicrobial therapy, we recommend daily assessment (e.g., clinical, laboratory assessment) for de-escalation of antimicrobial therapy in consultation with infectious diseases specialists. Stopping of antimicrobial therapy should be considered depending on the clinical course, microbiological findings, and the presence of PIMS-TS diagnostic criteria, including evidence of recent or current SARS-CoV-2 infection by serology or PCR.

Remdesivir, a nucleoside analog prodrug, has been approved for the treatment of COVID-19 in adults based on emerging evidence demonstrating the efficacy in shortening time to clinical recovery (51, 52), however recent experience (51, 53) has not confirmed these findings. The safety and effectiveness of remdesivir for treatment of COVID-19 in children has not yet been evaluated (studies are underway) outside case reports (54, 55). Hence the role of remdesivir in the management of PIMS-TS is uncertain, especially as PIMS-TS represents a post-infectious disorder rather than active SARS-CoV-2 infection. For these reasons the panel agreed that remdesivir should not be routinely used in children with PIMS-TS. However, PIMS-TS patients may be considered for the compassionate use of remdesivir on a case-by-case basis (31, 56). When remdesivir is used the FDA emergency use authorization instructions for the use of remdesivir in children >3.5 kg should be followed (57).

Children with PIMS-TS initially often present with signs and symptoms that mimic those of septic shock and toxic shock syndrome (34) and neither clinical findings (fever, rash, abdominal symptoms), infection markers (CRP), nor other laboratory measures of inflammation may allow reliable discrimination (58, 59). Mortality in children with sepsis and septic shock increases as time to effective antimicrobial therapy increases (60, 61). All suspected PIMS-TS patients with clinical signs of sepsis should therefore receive prompt empiric intravenous antibiotics within 1 h of presentation for those with shock, and within up to 3 h for those without shock (60). The choice of antibiotics should be based on local guidelines and taking into account age, epidemiology, signs consistent with toxic shock, and pre-existing medical conditions. Antibiotics should be stream-lined or stopped on the basis of the clinical course and microbiological culture results in discussion with the infectious diseases team.

Supportive Measures

16. All PIMS-TS patients with shock or other organ dysfunction must be transferred to a center with availability of specialized Pediatric Intensive Care Units, cardiology, infectious diseases, and immunology/rheumatology.

17. Hemodynamic, respiratory, and other organ support should follow established guidelines such as the Surviving Sepsis Campaign.

18. Extracorporeal Membrane Oxygenation should be considered in PIMS-TS with cardiac, respiratory, or cardiorespiratory failure refractory to conventional management as per established guidelines such as the Surviving Sepsis Campaign.

Many PIMS-TS patients do not show evidence of active viral infection and may be less likely to be infectious to healthcare workers. However, clinical staff should wear appropriate personal protective equipment (31) as per institutional guidelines. Children should be triaged, assessed and management in line with recommendations for management of fever in infants <36 months, Surviving Sepsis Campaign (60), and standard Pediatric Advanced Life Support resuscitation algorithms for critically ill children. As some children's condition may worsen rapidly and they may develop hemodynamic compromise, close monitoring and early referral to a center with expertise in pediatric cardiology and PICU is mandatory. During resuscitation with fluid boluses, repeated assessment for signs of fluid overload is warranted (58) given risks associated with fluid overload, and considering that myocardial involvement is often seen in PIMS-TS.

19. In the absence of contraindications, we recommend starting prophylactic i.v. unfractionated heparin at a dose of 10 U/kg/h in PIMS-TS patients with shock. Conversion to low molecular weight heparin (LMWH, such as enoxaparin at a dose of 0.5 mg/kg q12 h) after the first day should be considered, depending on renal function.

20. In any other PIMS-TS patient requiring intensive care admission, we recommend prophylactic heparin (at a dose of 10 U/kg/h) or low molecular weight heparin (LMWH, such as enoxaparin at a dose of 0.5 mg/kg s.c. q12 h) depending on renal function.

21. For PIMS-TS patients not requiring PICU care, individual risk factors for thrombotic complications should be assessed to guide decisions on individualized anticoagulation therapy.

22. In all patients with coronary artery abnormalities antiplatelet management should follow established guidelines for Kawasaki disease.

23. As all patients with PIMS-TS irrespective of their phenotype are at risk for coronary artery aneurysms it is reasonable to administer low-dose acetyl salicylic acid (3–5 mg/kg, max. 100 mg) in all patients at least for 4–6 weeks until coronary abnormalities have been ruled out.

While there are only scarce data on the use of anticoagulation in children with PIMS-TS (40), there seems to be an increased risk of thromboembolic complications in patients infected with COVID-19, and as well during acute PIMS-TS (17, 62). These risks may potentiate the baseline risk of thromboembolic complications in critically ill children exposed to central venous devices, immobility, and other procedures (63). Therefore, the panel suggested to use prophylactic anticoagulation in those patients of higher severity requiring PICU admission. Clinicians should always weigh benefit of antiplatelet and anticoagulation treatments against the individual risk for clinically relevant bleeding. In acutely critically ill patients with shock the clinical course may rapidly change. For this reason we suggest starting with heparin rather than LMWH to enable stopping or reversal if clinically relevant bleeding occurs, and to avoid accumulation if renal function deteriorates.

In non-PICU patients, the overall assessment of the individual risk profile should include well-established risk factors such as a previous history of venous thromboembolism or a first-degree relative with venous thromboembolism, the presence of a central line, post-pubertal age or estrogen therapy amongst other. In addition, obesity may increase risk for thromboembolic events in patients with SARS-CoV-2 infection or PIMS-TS.

Similar to classical KD patients, children with PIMS-TS irrespective of the phenotype may be at risk for the development of coronary artery aneurysms. Hence it appears to be reasonable to consider low dose aspirin (3–5 mg/kg, maximum 100 mg, q24 h) in addition to prophylactic anticoagulation in all patients with PIMS-TS.

Discharge From Hospital and Proposed Follow-Up

24. Patients who have been clinically well on regular wards with evidence of normal or recovering cardiac function, and who have been afebrile (<38 degrees) for 48 h should be considered for discharge home after MDT review.

25. A multi-disciplinary follow up is recommended for all patients at least after 1–2 weeks, and 4–6 weeks, respectively, post discharge from hospital. Follow-up should include pediatric immunology/rheumatology and cardiology, and, depending on the presentation and severity, other disciplines.

26. In case of cardiac involvement, cardiac follow up should be performed at least at 3, 6, and 12 months after discharge (Table 4).

TABLE 4

Table 4. Proposed recommendations for clinical follow-up of PIMS-TS patients post-discharge.

Hospitals who do not have access to pediatric immunology, cardiology, or intensive care services should consult with the respective centers. In all children with PIMS-TS irrespective of the phenotype, consultation with cardiology is recommended before discharge to guide frequency of follow-up echocardiographic assessment, as cardiac function may not have fully normalized by the time of discharge and aneurysms may develop later in the course of the disease, even post-discharge. In general, we suggest performing a follow-up visit 1–2 weeks, and 4–6 weeks, respectively, after discharge which should encompass a multidisciplinary consultation. The visits should serve as well to critically review the indication, dosing, and duration of ongoing immunosuppressive therapy as appropriate. There is no evidence on duration and tapering schedules of steroids in PIMS-TS, nor on the recommended duration of hospitalization. Decisions on post-discharge treatment thus should be guided by ongoing laboratory or clinical evidence for persistent inflammation.

In children with cardiac manifestations, extension of the follow-up is recommended, and specific cardiac follow up is dependent on the degree of initial cardiac involvement, persistent myocardial dysfunction, coronary artery abnormalities, or rhythm disturbances. For all patients with coronary artery abnormalities a cardiologic follow up according to the American Heart Association KD guidelines is recommended (30). Hence, careful follow up should be considered to monitor myocardial function and coronary artery changes. Table 4 provides a suggestion on follow-up but it is important to acknowledge the lack of data to inform best follow-up practice at the present stage.

Exercise restriction is recommended for 2 weeks from discharge if there is no cardiac involvement; for 3–6 months if cardiac involvement was documented. ECG, echocardiography, exercise stress test and Holter monitor should be performed before resuming sport activity and cTnT and NT-pro-BNP should be normalized (27).

Discussion

Within months of the COVID-19 pandemic spread, many countries across the globe have reported children presenting unwell with features of severe inflammation and multisystem disease (64, 65). Using available literature and guidelines from international institutions, the Swiss PIMS-TS recommendations represent best practice guidelines based on currently available knowledge to facilitate and standardize treatment of children with suspected PIMS-TS in Switzerland. The available literature is limited to retrospective and prospective studies from different part of the world (66, 67). There are no trials comparing different treatment modalities. The guidance on using various immunomodulatory agents is therefore limited to data from these observational cohort studies and indirect evidence from other hyperinflammatory conditions in children and adults.

These recommendation were established in exchange with experts from the U.K. and, accordingly, leverage from the RCPCH case definition. In comparison to another recently published institutional protocol on PIMS-TS from New York (26), our algorithm stratifies by severity defined as shocked/non-shocked rather than using specific vasopressor thresholds which are usually not applicable outside the intensive care environment. For children without shock presenting with undifferentiated PIMS-TS presentations, IVIG should be considered by the MDT team.

A number of limitations need to be considered. First, while the expert group includes specialists from the relevant disciplines, numbers of children with PIMS-TS during the first wave of COVID-19 in Switzerland were low, limiting experience in managing the disease (14, 45). However, the group assessed institutional pathways from other health care systems and consulted world leading experts in the field during the process. Second, the literature review performed was not systematic but focused. Third, to date there are no published results from randomized controlled trials in the field, and the evidence base for optimal PIMS-TS management remains minimal. Finally, recommendations were issued in the context of a well-resourced setting, where IVIG and biologicals are relatively easily available, and may not be applicable to resource limited settings. In relation to applying these guidelines, clinicians should be mindful of the risk of anchoring bias during the pandemic. Many children may test positive for COVID-19, not necessarily implying causality. The CDC, WHO and RCPCH case definitions of PIMS-TS bear a risk to over diagnose an assumedly rare syndrome in children who suffer from other common infectious or inflammatory or conditions such as septic shock, or rarer conditions such as HLH.

In conclusion, it is imperative that children with PIMS-TS are enrolled in prospective trials where feasible (68–70), and that clinical data are collected and shared to improve our understanding of the disease and its best management. Given the absence of high-grade evidence (20), regular revisions of these recommendations will be required when more evidence becomes available.

Author Contributions

LS and PR designed and coordinated the work, wrote the first draft, and take responsibility for the content of the work. MA, NS, SG, and NR led subgroups and wrote the first draft on their section. All other authors participated in literature review, voting, writing, and have seen and approved the final version.

Funding

LS received funding from the NOMIS foundation, GAYDOUL foundation, and VONTOBEL foundation for a trial in children with PIMS-TS.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank Laura Chapuisat, Swiss Society of Intensive Care, for the administrative support during the project and voting. We thank Prof. Mike Levin, and EW, Imperial College London, for their valuable advice.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2021.667507/full#supplementary-material

References

1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. (2020) 383:2451–60. doi: 10.1056/NEJMcp2009575

CrossRef Full Text | Google Scholar

2. Levin M. Childhood multisystem inflammatory syndrome - a new challenge in the pandemic. N Engl J Med. (2020) 383:393–95. doi: 10.1056/NEJMe2023158

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Rimensberger PC, Kneyber MCJ, Deep A, Bansal M, Hoskote A, Javouhey E, et al. Neonatal intensive care scientific sections' collaborative, caring for critically ill children with suspected or proven coronavirus disease 2019 infection: recommendations by the scientific sections' collaborative of the European Society of Pediatric and Neonatal Intensive Care. Pediatr Crit Care Med. (2021) 22:56–67. doi: 10.1097/PCC.0000000000002599

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. (2020) 324:259–69. doi: 10.1001/jama.2020.10369

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al., Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. (2020) 383:334–46. doi: 10.1056/NEJMoa2021680

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Guidance: Paediatric Multisystem Inflammatory Syndrome Temporally Associated With COVID-19. RCPCH (2020). Available online at: https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance

7. C.f.Control D. Multisystem Inflammatory Syndrome (MIS-C) (2020). Available online at: https://www.cdc.gov/mis-c/

8. World Health Organisation. Multisystem Inflammatory Syndrome in Children and Adolescents With COVID-19 (2020). Available online at: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19

Google Scholar

9. Carter MJ, Shankar-Hari M, Tibby SM. Paediatric inflammatory multisystem syndrome temporally-associated with SARS-CoV-2 infection: an overview. Intensive Care Med. (2021) 47:90–3. doi: 10.1007/s00134-020-06273-2

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine. (2020) 26:100527. doi: 10.1016/j.eclinm.2020.100527

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell. (2020) 183:982–95 e14. doi: 10.1016/j.cell.2020.09.034

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Carter MJ, Fish M, Jennings A, Doores KJ, Wellman P, Seow J, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. (2020) 26:1701–7. doi: 10.1038/s41591-020-1054-6

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Lee PY, Day-Lewis M, Henderson LA, Friedman KG, Lo J, Roberts JE, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest. (2020) 130:5942–50. doi: 10.1172/JCI141113

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Grazioli S, Tavaglione F, Torriani G, Wagner N, Rohr M, L'Huillier AG, et al. Immunological assessment of pediatric multisystem inflammatory syndrome related to COVID-19. J Pediatric Infect Dis Soc. (2020) piaa142. doi: 10.1093/jpids/piaa142

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. (2020) 183:968–81 e7. doi: 10.1016/j.cell.2020.09.016

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol. (2020) 20:453–4. doi: 10.1038/s41577-020-0367-5

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Goldenberg NA, Sochet A, Albisetti M, Biss T, Bonduel M, Jaffray J, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. (2020) 18:3099–105. doi: 10.1111/jth.15073

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Alsaied T, Tremoulet AH, Burns JC, Saidi A, Dionne A, Lang SM, et al. Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation. (2021) 143:78–88. doi: 10.1161/CIRCULATIONAHA.120.049836

PubMed Abstract | CrossRef Full Text | Google Scholar

19. McMurray JC, May JW, Cunningham MW, Jones OY. Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis-a critical review of its pathogenesis and treatment. Front Pediatr. (2020) 8:626182. doi: 10.3389/fped.2020.626182

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Davey Smith G, Blastland M, Munafo M. Covid-19's known unknowns. BMJ. (2020) 371:m3979. doi: 10.1136/bmj.m3979

CrossRef Full Text | Google Scholar

21. Nijman RG, De Guchtenaere A, Koletzko B, Ross Russell R, Copley S, Titomanlio L, et al. Pediatric inflammatory multisystem syndrome: statement by the pediatric section of the European Society for Emergency Medicine and European Academy of Pediatrics. Front Pediatrics. (2020) 8:490. doi: 10.3389/fped.2020.00490

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. (2020) 79:999–1006. doi: 10.1136/annrheumdis-2020-217960

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Bautista-Rodriguez C, Sanchez-de-Toledo J, Clark BC, Herberg J, Bajolle F, Randanne PC, et al. Multisystem inflammatory syndrome in children: an international survey. Pediatrics. (2021) 147:e2020024554. doi: 10.1542/peds.2020-024554

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Dove ML, Jaggi P, Kelleman M, Abuali M, Ang JY, Ballan W, et al. Multisystem inflammatory syndrome in children: survey of protocols for early hospital evaluation and management. J Pediatr. (2021) 229:33–40. doi: 10.1101/2020.07.29.20164459

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. (2021) 5:133–41. doi: 10.1016/S2352-4642(20)30304-7

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Jonat B, Gorelik M, Boneparth A, Geneslaw AS, Zachariah P, Shah A, et al. Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York city: patient characteristics and an institutional protocol for evaluation, management, and follow-up. Pediatr Crit Care Med. (2021) 22:e178–91. doi: 10.1097/PCC.0000000000002598

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. (2021) 180:307–22. doi: 10.1007/s00431-020-03766-6

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance. American Academy of Pediatrics (2020). Available online at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/

Google Scholar

29. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. (2005) 6:2–8. doi: 10.1097/01.PCC.0000149131.72248.E6

PubMed Abstract | CrossRef Full Text | Google Scholar

30. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. (2017) 135:e927–99. doi: 10.1161/CIR.0000000000000484

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. (2020) 5:133–41. doi: 10.1101/2020.07.17.20156075

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A, Di Filippo S, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. (2021) 143:21–32. doi: 10.2139/ssrn.3634853

PubMed Abstract | CrossRef Full Text | Google Scholar

33. White M, Tiesman B, Handforth J, Kenny J. Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): the Evelina Experience. Arch Dis Child. (2020) 105:1025–7. doi: 10.1136/archdischild-2020-319554

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Weiss SL, Peters MJ, Agus MSD, Alhazzani W, Choong K, Flori HR, et al. Perspective of the surviving sepsis campaign on the management of pediatric sepsis in the era of coronavirus disease 2019. Pediatr Crit Care Med. (2020) 21:e1031–7. doi: 10.1097/PCC.0000000000002553

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Choi NH, Fremed M, Starc T, Weller R, Cheung E, Ferris A, et al. MIS-C and cardiac conduction abnormalities. Pediatrics. (2020) 146:e2020009738. doi: 10.1542/peds.2020-009738

CrossRef Full Text | Google Scholar

36. Dionne A, Mah DY, Son MBF, Lee PY, Henderson L, Baker AL, et al. Atrioventricular block in children with multisystem inflammatory syndrome. Pediatrics. (2020) 146:e2020009704. doi: 10.1542/peds.2020-009704

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Matsubara D, Kauffman HL, Wang Y, Calderon-Anyosa R, Nadaraj S, Elias MD, et al. Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. J Am Coll Cardiol. (2020) 76:1947–61. doi: 10.1016/j.jacc.2020.08.056

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. (2020) 395:1607–8. doi: 10.1016/S0140-6736(20)31094-1

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. (2020) 395:1771–8. doi: 10.1016/S0140-6736(20)31103-X

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol. (2020) 72:1791–805. doi: 10.1002/art.41454

PubMed Abstract | CrossRef Full Text | Google Scholar

41. de Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology. (2019) 58:672–82. doi: 10.1093/rheumatology/key344

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Belhadjer Z, Auriau J, Meot M, Oualha M, Renolleau S, Houyel L, et al. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. (2020) 142:2282–4. doi: 10.1161/CIRCULATIONAHA.120.050147

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. (2021) 325:855–64. doi: 10.1001/jama.2021.0694

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. (2010) 11:234–8. doi: 10.1097/PCC.0b013e3181b806fc

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Fouriki A, Fougere Y, De Camaret C, Blanchard Rohner G, Grazioli S, Wagner N, et al. Case report: case series of children with multisystem inflammatory syndrome following SARS-CoV-2 infection in Switzerland. Front Pediatr. (2020) 8:594127. doi: 10.3389/fped.2020.594127

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-0

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. (2020) 2:e358–67. doi: 10.1016/S2665-9913(20)30096-5

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Galea J, Ogungbenro K, Hulme S, Greenhalgh A, Aarons L, Scarth S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. (2011) 31:439–47. doi: 10.1038/jcbfm.2010.103

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Martinez OM, Bridges ND, Goldmuntz E, Pascual V. The immune roadmap for understanding multi-system inflammatory syndrome in children: opportunities and challenges. Nat Med. (2020) 26:1819–24. doi: 10.1038/s41591-020-1140-9

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Diorio C, Henrickson SE, Vella LA, McNerney KO, Chase J, Burudpakdee C, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. (2020) 130:5967–75. doi: 10.1172/JCI140970

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. (2020) 383:1813–26. doi: 10.1056/NEJMoa2007764

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Rochwerg B, Agarwal A, Zeng L, Leo YS, Appiah JA, Agoritsas T, et al. Remdesivir for severe covid-19: a clinical practice guideline. BMJ. (2020) 370:m2924. doi: 10.1136/bmj.m2924

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 395:1569–78. doi: 10.1016/S0140-6736(20)31022-9

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Orf K, Rogosic S, Dexter D, Ancliff P, Badle S, Brierley J, et al. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. Br J Haematol. (2020) 190:e274–6. doi: 10.1111/bjh.17014

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc. (2020) 10:34–48. doi: 10.1093/jpids/piaa045

CrossRef Full Text | Google Scholar

56. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. (2020) 323:1824–36. doi: 10.1001/jama.2020.6019

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Food and Drug Administration. Fact sheet for healthcare providers emergency use authorization (EUA) of veklury® (remdesivir) for hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 KG (2020). Available online at: https://www.fda.gov/media/137566/download

58. Schlapbach LJ. Paediatric sepsis. Curr Opin Infect Dis. (2019) 32:497–504. doi: 10.1097/QCO.0000000000000583

CrossRef Full Text | Google Scholar

59. Schlapbach LJ, Kissoon N. Defining pediatric sepsis. JAMA Pediatr. (2018) 172:312–4. doi: 10.1001/jamapediatrics.2017.5208

CrossRef Full Text | Google Scholar

60. Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Intensive Care Med. (2020) 46:10–67. doi: 10.1007/s00134-019-05878-6

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Evans IVR, Phillips GS, Alpern ER, Angus DC, Friedrich ME, Kissoon N, et al. Association between the New York sepsis care mandate and in-hospital mortality for pediatric sepsis. JAMA. (2018) 320:358–67. doi: 10.1001/jama.2018.9071

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. (2020) 4:6051–63. doi: 10.1182/bloodadvances.2020003471

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Polikoff LA, Faustino EV. Venous thromboembolism in critically ill children. Curr Opin Pediatr. (2014) 26:286–91. doi: 10.1097/MOP.0000000000000084

CrossRef Full Text | Google Scholar

64. Antunez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-Sarachaga M, Salcedo-Lozada P, et al. COVID-19 and multisystem inflammatory syndrome in latin american children: a multinational study. Pediatr Infect Dis J. (2021) 40:e1–6. doi: 10.1097/INF.0000000000002949

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Garcia-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramirez J, Slocker Barrio M, Leoz Gordillo I, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. (2020) 24:666. doi: 10.1186/s13054-020-03332-4

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Williams V, Dash N, Suthar R, Mohandoss V, Jaiswal N, Kavitha TK, et al. Clinicolaboratory profile, treatment, intensive care needs, and outcome of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2: a systematic review and meta-analysis. J Pediatric Intensive Care. (2020). doi: 10.1055/s-0040-1719173

CrossRef Full Text | Google Scholar

67. Kaushik S, Aydin SI, Derespina KR, Bansal PB, Kowalsky S, Trachtman R, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York city. J Pediatr. (2020) 224:24–9. doi: 10.1016/j.jpeds.2020.06.045

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Garcia-Prats AJ, Salazar-Austin N, Conway JH, Radtke K, LaCourse SM, Maleche-Obimbo E, et al. Coronavirus disease 2019 (COVID-19) pharmacologic treatments for children: research priorities and approach to pediatric studies. Clin Infect Dis. (2021) 72:1067–73. doi: 10.1093/cid/ciaa885

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Goldman RD, Staubli G, Cotanda CP, Brown JC, Hoeffe J, Seiler M, et al. Factors associated with parents' willingness to enroll their children in trials for COVID-19 vaccination. Hum Vaccin Immunother. (2020) 17:1–5. doi: 10.1080/21645515.2020.1834325

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Campbell JI, Ocwieja KE, Nakamura MM. A call for pediatric COVID-19 clinical trials. Pediatrics. (2020) 146:e20201081. doi: 10.1542/peds.2020-1081

PubMed Abstract | CrossRef Full Text | Google Scholar